Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Behcet’s Uveitis Therapy (BUT) Study
ChiCTR2000031637Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Apr 2020
- Modality
- Small Molecules, Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of interferon alfa-2a, adalimumab and cyclosporine in uveitis and Behçet's disease (BD) (3 arms), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoint: Annualized relapse rate of uveitis in Behcet’s disease. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
03
Conditions
uveitisBehçet's disease (BD)
Beyond the preview
Go deeper on ChiCTR2000031637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031637.